Antisense Oligonucleotides Directed against Human ELAM-I RNA.
Patent, Filed 12 Oct 93, patented 17 Dec 96,
DEPARTMENT OF THE NAVY WASHINGTON DC
Pagination or Media Count:
The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ELAM-I mRNA transcript using at least one oligonucleotide which is substantially complementary to at least a portion of the ELAM-I gene is disclosed, as are composition comprising the oligonucleotide
- Medicine and Medical Research